Pharmacyclics LLC - Company Profile
Powered by 
All the data and insights you need on Pharmacyclics LLC in one report.
$295
- Save hours of research time and resources with
our up-to-date Pharmacyclics LLC Strategy Report
- Understand Pharmacyclics LLC position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pharmacyclics LLC (Pharmacyclics), a subsidiary of AbbVie Inc, is a biopharmaceutical company which focuses on the development and commercialization of small-molecule medicines for the treatment of cancer and immune-mediated diseases. The company’s marketed product includes Imbruvica is an once-daily, first-in-class bruton's tyrosine kinase (BTK) inhibitor developed for the treatment of patients with chronic lymphocytic leukemia, waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma and chronic graft-versus-host disease. Its products candidate in clinical development includes Imbruvica BTK inhibitor intended for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, graft versus host disease, mature B-cell non-hodgkin lymphomas, and solid tumors, among others. Pharmacyclics is headquartered in Sunnyvale, California, the US.
Headquarters
United States of America
Address
999 East Arques Avenue, Sunnyvale, California, 94085
Website
www.pharmacyclics.com
Telephone
1 408 2153000
Industry
Pharmaceuticals and Healthcare
Pharmacyclics LLC premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Products | Imbruvica |
| Imbruvica (ibrutinib): | |
| Chronic Lymphocytic Leukemia | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In July, the company entered into a clinical trial collaboration with Oncternal Therapeutics for the supply of ibrutinib will support the company’s Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory mantle cell lymphoma, ZILO-301. |
| 2020 | New Product Approvals | In April, the company's parent company AbbVie received US FDA approval for use of Imbruvica in combination with rituximab for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL). |
| 2019 | New Product Approvals | In January, Pharmacyclics’ parent company, AbbVie, received an approval for its Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) from the US FDA. |
Competitor Comparison
| Key Parameters | Pharmacyclics LLC | Pharming Group NV | CTI BioPharma Corp | Ambrilia Biopharma Inc | Aphios Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | Netherlands | United States of America | Canada | United States of America |
| City | Sunnyvale | Leiden | Seattle | Montreal | Woburn |
| State/Province | California | - | Washington | Quebec | Massachusetts |
| No. of Employees | - | 390 | 128 | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wulff-Erik von Borcke | President | Senior Management | 2015 | - |
| Stefan Geldmeyer | Head - Finance and Infrastructure | Senior Management | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward